Cyclopharm (ASX:CYC) said the United States Patent and Trademark Office has approved a patent extension for the company's lung imaging technology, extending protection to 2031 from the original expiration date of 2026, according to a Wednesday filing with the Australian bourse.
The patent extension ensures uninterrupted US market exclusivity for the technology, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.